Edgar Argulian

Edgar Argulian

Auto-generated profile, based on publicly available information

Edgar Argulian

Department of Cardiology, Mount Sinai Morningside, Icahn School of Medicine at Mount Sinai , New York, NY

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in JACC
Verified
Journal Article
Closed access
SUSeth Uretsky
Seth Uretsky
LGLinda Gillam
Linda Gillam
RLRoberto Lang
Roberto Lang
FCFarooq A. Chaudhry
Farooq A. Chaudhry
EAEdgar Argulian
Edgar Argulian
SWSteven D. Wolff
Steven D. Wolff

6 November 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
AVAkhil Vaid
Akhil Vaid
SSSulaiman Somani
Sulaiman Somani
ARAdam J Russak
Adam J Russak
JFJessica K De Freitas
Jessica K De Freitas
FCFayzan Chaudhry
Fayzan Chaudhry
BGBenjamin S Glicksberg
Benjamin S Glicksberg
Background: COVID-19 has infected millions of people worldwide and is responsible for several hundred thousand fatalities. The COVID-19 pandemic has necessitated thoughtful resource allocation and early identification of high-risk patients. However, effective methods to meet these needs are lacking. Objective: The aims of this study were to analyze the electronic health records (EHRs) of patients who tested positive for COVID-19 and were admitted to hospitals in the Mount Sinai Health System in New York City; to develop machine learning models for making predictions about the hospital course of the patients over clinically meaningful time horizons based on patient characteristics at admission; and to assess the performance of these models at multiple hospitals and time points. Methods: We used Extreme Gradient Boosting (XGBoost) and baseline comparator models to predict in-hospital mortality and critical events at time windows of 3, 5, 7, and 10 days from admission. Our study population included harmonized EHR data from five hospitals in New York City for 4098 COVID-19–positive patients admitted from March 15 to May 22, 2020. The models were first trained on patients from a single hospital (n=1514) before or on May 1, externally validated on patients from four other hospitals (n=2201) before or on May 1, and prospectively validated on all patients after May 1 (n=383). Finally, we established model interpretability to identify and rank variables that drive model predictions. Results: Upon cross-validation, the XGBoost classifier outperformed baseline models, with an area under the receiver operating characteristic curve (AUC-ROC) for mortality of 0.89 at 3 days, 0.85 at 5 and 7 days, and 0.84 at 10 days. XGBoost also performed well for critical event prediction, with an AUC-ROC of 0.80 at 3 days, 0.79 at 5 days, 0.80 at 7 days, and 0.81 at 10 days. In external validation, XGBoost achieved an AUC-ROC of 0.88 at 3 days, 0.86 at 5 days, 0.86 at 7 days, and 0.84 at 10 days for mortality prediction. Similarly, the unimputed XGBoost model achieved an AUC-ROC of 0.78 at 3 days, 0.79 at 5 days, 0.80 at 7 days, and 0.81 at 10 days. Trends in performance on prospective validation sets were similar. At 7 days, acute kidney injury on admission, elevated LDH, tachypnea, and hyperglycemia were the strongest drivers of critical event prediction, while higher age, anion gap, and C-reactive protein were the strongest drivers of mortality prediction. Conclusions: We externally and prospectively trained and validated machine learning models for mortality and critical events for patients with COVID-19 at different time horizons. These models identified at-risk patients and uncovered underlying relationships that predicted outcomes.

1 January 2017 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
AGAnna Gu
Anna Gu
YYYu Yue
Yu Yue
RDRaj P. Desai
Raj P. Desai
EAEdgar Argulian
Edgar Argulian
Background—A key to reduce and eradicate racial disparities in hypertension outcomes is to understand their causes. We aimed at evaluating racial differences in antihypertensive drug utilization patterns and blood pressure control by insurance status, age, sex, and presence of comorbidities. Methods and Results—A total of 8796 hypertensive individuals ≥18 years of age were identified from the National Health and Nutrition Examination Survey (2003–2012) in a repeated cross-sectional study. During the study period, all 3 racial groups (whites, blacks, and Hispanics) experienced substantial increase in hypertension treatment and control. The overall treatment rates were 73.9% (95% confidence interval [CI], 71.6%–76.2%), 70.8% (95% CI, 68.6%–73.0%), and 60.7% (95% CI, 57.0%–64.3%) and hypertension control rates were 42.9% (95% CI, 40.5%–45.2%), 36.9% (95% CI, 34.7%–39.2%), and 31.2% (95% CI, 28.6%–33.9%) for whites, blacks, and Hispanics, respectively. When stratified by insurance status, blacks (odds ratio, 0.74 [95% CI, 0.64–0.86] for insured and 0.59 [95% CI, 0.36–0.94] for uninsured) and Hispanics (odds ratio, 0.74 [95% CI, 0.60–0.91] for insured and 0.58 [95% CI, 0.36–0.94] for uninsured) persistently had lower rates of hypertension control compared with whites. Racial disparities also persisted in subgroups stratified by age (≥60 and <60 years of age) and presence of comorbidities but worsened among patients <60 years of age. Conclusions—Black and Hispanic patients had poorer hypertension control compared with whites, and these differences were more pronounced in younger and uninsured patients. Although black patients received more intensive antihypertensive therapy, Hispanics were undertreated. Future studies should further explore all aspects of these disparities to improve cardiovascular outcomes.

1 July 2006 in The American Journal of Cardiology
Verified
Journal Article
Closed access
EAEdgar Argulian
Edgar Argulian
APAmar D. Patel
Amar D. Patel
JAJerome L. Abramson
Jerome L. Abramson
AKAniket Kulkarni
Aniket Kulkarni
KCKimberly Champney
Kimberly Champney
VVViola Vaccarino
Viola Vaccarino

1 October 2013 in The American Journal of Medicine
Verified
Journal Article
Closed access
EAEdgar Argulian
Edgar Argulian
FMFranz Messerli
Franz Messerli

1 November 2016 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
CBChirag Bavishi
Chirag Bavishi
KBKiruthika Balasundaram
Kiruthika Balasundaram
EAEdgar Argulian
Edgar Argulian